- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Brian F. Chapin, M.D. on the Uptake of PSMA PET in Prostate Imaging
The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?
This content originally appeared on our sister site, Urology Times.
Prostate cancer imaging is having its moment in the spotlight, with numerous advances in imaging agents for positron emission tomography slated to help improve diagnostics in a disease that's rife with recurrence.
The most recent news comes from Blue Earth Diagnostics, whose radioactive imaging agent Posluma (flotufolastat F 18) was recently approved in May 2023 for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
While improved imaging will certainly move the needle on diagnosis, it's yet to be seen how this will ultimately impact patient outcomes.
In an interview with our sister site, Urology Times, Brian F. Chapin, M.D., associate professor of urology at the University of Texas MD Anderson Cancer Center in Houston, spoke about the potential impact of PSMA PET and some of the challenges the clinical community is facing in the wake of these advances.
Click here for more of the latest research on prostate imaging.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC
January 24th 2025Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
